The Blood Test That Catches Breast Cancer Fighting Back
The FDA just approved a blood test that catches breast cancer outsmarting its own treatment, months before a scan would. Paired with AstraZeneca's new drug camizestrant, it could reshape how oncologists fight treatment resistance in real time.
Imagine you're fighting a war, and your enemy starts wearing a disguise. Your weapons stop working, but you don't realize it until months later when the damage is already done. That's essentially what happens when breast cancer mutates to resist treatment. But now, a simple blood draw can catch the betrayal before it shows up on a scan.
On September 4, 2026, the FDA approved Guardant Health's Guardant360 CDx as a companion diagnostic for AstraZeneca's newly greenlit oral drug camizestrant (brand name: Etcamah). Together, the pair represent something oncologists have been chasing for years: a way to detect treatment resistance in real time and switch therapies before the cancer gains ground.
The Mutation That Hijacks Treatment
To understand why this matters, you need to know about ESR1 mutations. Think of the estrogen receptor as a lock on the surface of certain breast cancer cells. Normally, estrogen is the key that opens it and tells the cell to grow. Aromatase inhibitors (a standard treatment) work by hiding the keys, starving the cancer of estrogen.
But some tumors get clever. They mutate the lock so it stays permanently open, no key required. That's an ESR1 mutation: the cancer learns to grow without estrogen, making the treatment useless.
These mutations are sneaky. They're rare in early-stage disease (roughly 0.5% to 3% of primary tumors), but they show up in 15% to 40% of patients with metastatic, treatment-exposed breast cancer. The longer someone is on aromatase inhibitors, the more likely the cancer is to develop this escape hatch. And until now, doctors often didn't catch it until a scan showed the tumor growing again.
That's months of wasted time on a therapy that stopped working.
A Liquid Biopsy That Doesn't Wait Around
Guardant's test changes the playbook. Instead of waiting for a scan to reveal bad news, Guardant360 CDx detects ESR1 mutations from a blood draw. It picks up tiny fragments of tumor DNA circulating in the bloodstream (called ctDNA, or circulating tumor DNA), and Guardant recommends repeating the test during therapy.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
every three months
Picture it like a smoke detector versus waiting to see flames. The blood test catches the molecular smoke long before the radiographic fire.
This is what makes the pairing with camizestrant so powerful. Camizestrant is an oral SERD (selective estrogen receptor degrader), a drug designed to destroy the estrogen receptor entirely rather than just blocking it. If the receptor mutates and stays open? Camizestrant tears the whole lock off the door.
The FDA approved camizestrant in combination with a CDK4/6 inhibitor (drugs like palbociclib, ribociclib, or abemaciclib) specifically for HR-positive, HER2-negative locally advanced or metastatic breast cancer when an ESR1 mutation is detected during standard treatment.
The Trial That Proved It Works
The approval rests on SERENA-6, a Phase III clinical trial that tested a straightforward idea: what if you switched patients to camizestrant the moment their blood test flagged an ESR1 mutation, rather than waiting for their disease to visibly progress?
The results, presented at ASCO 2025 and published in The New England Journal of Medicine, were striking. Patients who switched to camizestrant plus a CDK4/6 inhibitor saw a 56% reduction in the risk of disease progression or death compared to those who stayed on their existing regimen.
That's the kind of number that changes clinical practice.
It's worth noting that the FDA's advisory committee actually voted 6 to 3 against recommending the drug, a somewhat unusual split. The agency overruled the committee and granted accelerated approval anyway, which signals the FDA saw enough promise in the ctDNA-guided approach to move forward. The FDA did note, however, that patient-reported outcome data from the trial were exploratory and not considered evidence of clinical benefit.
The Oral SERD Wars Are Heating Up
Camizestrant isn't entering an empty market. It's the fourth oral SERD to win FDA approval, and the competition is getting fierce.
Elacestrant (from Menarini/Stemline) was the trailblazer, the first oral SERD approved, based on its EMERALD trial data showing improved progression-free survival in ESR1-mutated disease. Eli Lilly's imlunestrant followed with its own approval in September 2025 for ESR1-mutated advanced breast cancer after endocrine therapy progression. Roche's giredestrant has an NDA under FDA review with a decision expected by late 2026.
So what makes camizestrant different? The ctDNA-guided strategy. While elacestrant and imlunestrant are positioned for patients whose disease has already progressed, camizestrant's label is built around earlier interception: catching the mutation in the blood and switching treatment before the cancer visually advances. It's the difference between putting out a fire and installing a sprinkler system.
The competitive question for 2026 and beyond isn't whether oral SERDs work. It's which drug owns which clinical moment. Elacestrant holds the second-line niche. Imlunestrant competes in a similar space. Camizestrant is betting that catching resistance earlier will carve out a distinct, potentially larger, opportunity.
Guardant's Growing Empire
For Guardant Health, this approval is another trophy on an increasingly crowded shelf. The company now has 29 companion diagnostic indications globally across its Guardant360 CDx platform, spanning lung cancer, breast cancer, and colorectal cancer.
The 2025 and 2026 stretch alone has been prolific. In 2025, Guardant landed a CDx approval for Eli Lilly's imlunestrant. In 2026, it added approvals for Boehringer Ingelheim's zongertinib in HER2-mutant lung cancer, the Arvinas/Pfizer PROTAC vepdegestrant in ESR1-mutated breast cancer, and encorafenib plus cetuximab in BRAF V600E-mutant colorectal cancer. Now add camizestrant to the list.
Guardant is positioning itself as the default testing partner for precision oncology drugs, and each new approval deepens that moat. If your drug needs a biomarker test to identify the right patients, Guardant wants to be the answer.
Why This One Feels Different
Plenty of companion diagnostics exist. What makes this approval noteworthy is the longitudinal testing model: not a one-time test at diagnosis, but repeated blood draws every few months to monitor for emerging resistance. That's recurring revenue for Guardant and, more importantly, a fundamentally different relationship between testing and treatment.
It shifts oncology from "test once, treat, wait, scan, react" to something closer to a real-time feedback loop. Cancer mutates; the blood test catches it; the doctor switches therapy; the patient (hopefully) benefits. It's precision oncology operating the way it was always supposed to.
The 56% reduction in progression risk from SERENA-6 suggests the approach works. Now the real test begins: whether oncologists adopt the every-three-months testing cadence, whether payers cover it consistently, and whether this ctDNA-guided model becomes the new standard of care in HR-positive breast cancer.
If it does, a routine blood draw might become the most important weapon in the fight against treatment resistance. Not bad for a tube of blood.
Clinical & Regulatory
4 min read
The Immunotherapy Target Everyone Gave Up On Just Came Back to Life
Every major pharma company tried to make OX40 agonists work in cancer, and every single one failed. Now Inhibrx's hexavalent approach just delivered Phase 2 results that could resurrect an entire abandoned drug class.
